1. Home
  2. CGEM vs ADV Comparison

CGEM vs ADV Comparison

Compare CGEM & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.15

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

HOLD

Current Price

$35.01

Market Cap

438.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
ADV
Founded
2016
1987
Country
United States
United States
Employees
N/A
73000
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
438.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CGEM
ADV
Price
$14.15
$35.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$30.13
$45.83
AVG Volume (30 Days)
827.4K
68.9K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$0.63
Revenue Next Year
$5.20
$0.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$0.49
52 Week High
$16.74
$46.80

Technical Indicators

Market Signals
Indicator
CGEM
ADV
Relative Strength Index (RSI) 45.78 56.23
Support Level $13.75 $1.00
Resistance Level $16.10 $46.80
Average True Range (ATR) 1.05 3.95
MACD 0.01 -1.33
Stochastic Oscillator 37.50 19.40

Price Performance

Historical Comparison
CGEM
ADV

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

Share on Social Networks: